BR112012001931A2 - métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv - Google Patents

métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv

Info

Publication number
BR112012001931A2
BR112012001931A2 BR112012001931A BR112012001931A BR112012001931A2 BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2 BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A BR112012001931 A BR 112012001931A BR 112012001931 A2 BR112012001931 A2 BR 112012001931A2
Authority
BR
Brazil
Prior art keywords
diagnosing
outcome
methods
infected patients
hcv infected
Prior art date
Application number
BR112012001931A
Other languages
English (en)
Inventor
Pierre-Yves Bochud
Andri Rauch
Original Assignee
Centre Hospitalier Univ Vaudois
Univ Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Vaudois, Univ Of Bern filed Critical Centre Hospitalier Univ Vaudois
Publication of BR112012001931A2 publication Critical patent/BR112012001931A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
BR112012001931A 2009-07-31 2010-07-09 métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv BR112012001931A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH12012009 2009-07-31
US28253810P 2010-02-26 2010-02-26
PCT/IB2010/053139 WO2011013019A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Publications (1)

Publication Number Publication Date
BR112012001931A2 true BR112012001931A2 (pt) 2017-07-18

Family

ID=42727569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001931A BR112012001931A2 (pt) 2009-07-31 2010-07-09 métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv

Country Status (10)

Country Link
US (1) US20110165124A1 (pt)
EP (1) EP2459210A1 (pt)
JP (1) JP2013500713A (pt)
KR (1) KR20120040725A (pt)
CN (1) CN102665753A (pt)
AU (1) AU2010277239A1 (pt)
BR (1) BR112012001931A2 (pt)
CA (1) CA2768772A1 (pt)
MX (1) MX2012001058A (pt)
WO (1) WO2011013019A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656159B2 (ja) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 インターフェロン療法の効果予測用マーカー
BR112012018342A2 (pt) * 2009-12-22 2017-01-10 Janssen R&D Ireland "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente."
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
KR20140007927A (ko) * 2011-03-31 2014-01-20 노파르티스 아게 C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
US20140154209A1 (en) * 2011-06-30 2014-06-05 Centre Hospitalier Universitaire Vaudois Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
EA201490399A1 (ru) 2011-08-03 2014-06-30 Ситерис Иммунотерапия hcv (вируса гепатита c)
JP2013074888A (ja) * 2011-09-15 2013-04-25 Arkray Inc IL28B(rs8099917)とITPA(rs1127354)の変異を検出する方法
WO2013052862A1 (en) * 2011-10-05 2013-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetic marker for predicting prognosis in patients infected with hepatitis c virus
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
UY34401A (es) 2011-10-21 2013-05-31 Abbvie Inc Métodos para el tratamiento de hcv
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
WO2013148272A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A NOVEL INTERFERON-λ4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001050A (en) 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1997001603A1 (en) 1995-06-26 1997-01-16 Henkel Corporation Methods of preparing inorganic pigment dispersions
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
EP2360271A1 (en) 1998-06-24 2011-08-24 Illumina, Inc. Decoding of array sensors with microspheres
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
WO2006003654A2 (en) * 2004-07-01 2006-01-12 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients
JP2012501345A (ja) * 2008-08-28 2012-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド Hcv遺伝子型の分析
EA020795B1 (ru) * 2009-05-21 2015-01-30 Мерк Шарп Энд Домэ Корп. Генетические маркеры, ассоциированные с ответом на интерферон-альфа

Also Published As

Publication number Publication date
EP2459210A1 (en) 2012-06-06
CN102665753A (zh) 2012-09-12
MX2012001058A (es) 2012-06-19
US20110165124A1 (en) 2011-07-07
AU2010277239A1 (en) 2012-02-02
JP2013500713A (ja) 2013-01-10
KR20120040725A (ko) 2012-04-27
WO2011013019A1 (en) 2011-02-03
CA2768772A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
BR112012001931A2 (pt) métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv
BR112012000352A2 (pt) tapete ou tapete em placas
BRPI1015379A2 (pt) sistemas de cálculo biométrico e métodos
BR112012029417A2 (pt) detecção de análise de ataques maliciosos
BRPI0910608A2 (pt) métodos e sistemas para avaliar resultados clínicos
BRPI0906858A2 (pt) Métodos para detecção de assinaturas de doença ou condições em fluidos corporais
IL216472A0 (en) Benzoxazepines based p13k/mtor inhibitors against proliferative diseases
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BR112013014063A2 (pt) inibidores macrocíclicos do vírus flaviviridae
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
BR112012003876A2 (pt) mecanismos de trava de luva deslizante
IT1400425B1 (it) Modified snrnas for use in therapy.
BRPI1006988A2 (pt) mecanismo antitrapaça baseado em entidade confiável
PL2594588T3 (pl) Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
BRPI1015209A2 (pt) placa de osteossíntese com recurso de microincisões
FR2952508B3 (fr) Gant
BR112012003844A2 (pt) vacinas de pttv e diagnóstico
EP2754077A4 (en) GENOMIC TENSOR ANALYSIS FOR MEDICAL EVALUATION AND PREDICTION
BRPI0924140A2 (pt) pinça de microcirurgia, em particular pinça de capsulorrexe por microincisão
FI20085696A0 (fi) Liesiturvajärjestelmä
EP2649513A4 (en) SYSTEMS AND METHOD FOR VALIDATING OR VERIFYING LABORATORY TESTS
DK2612152T3 (da) Fremgangsmåde til at diagnosticere infektiøs peritonitis og forudsige sværhedsgraden og udfaldet deraf hos mennesker
IT1398372B1 (it) Gruppo di scarico sterilizzante
DE102010010272A8 (de) Vorrichtung zur Bereitstellung von heißen Abgasen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]